All In MedTech

Device Trial Radar · NCT02757547

Transcranial Magnetic Stimulation for Epilepsy

Registered Electrical Sources for Effective TMS Treatment of Epilepsy

Last checked: Nov 20, 2026Latest source record: Jul 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

2

Actual

Start

Sep 2015

Primary completion

Nov 15, 2017

Study completion Nov 15, 2017

Sponsor

Lead sponsor
Electrical Geodesics, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Stanford University
First posted
May 2, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the present clinical trial is to determine whether low frequency (0.5 Hz) rTMS can induce long term depression in epileptogenic cortex and thus suppress cortical excitability at the epileptic focus.

Conditions

  • Epilepsy

Interventions

  • Transcranial magnetic stimulation - Placebo ArmDevice

    Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.

  • Transcranial magnetic stimulation - Active ArmDevice

    Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Suppression of Seizure FrequencyTime frame: Placebo compared to Active

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.